Assembly Biosciences is a small, cash-burning biotech with quality metrics below the engine's floor and declining revenue, but a strong recent earnings beat streak and high modeled asymmetry keep speculative upside on the table.
Thesis pillars
- Quality Below Engine Floor→Stable
- Declining Revenue→Stable
- Institutionally Constrained Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Assembly Biosciences, Inc. (ASMB) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.89: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend.
Assembly Biosciences is a clinical-stage biotechnology company developing antiviral therapeutics, including two long-acting helicase-primase inhibitors for recurrent genital herpes (5366 and 1179, licensed to Gilead Sciences in December 2025), an oral hepatitis delta virus entry... Read more
Sell if holding. Engine safety override at $28.89: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Assembly Biosciences, Inc.
About Assembly Biosciences, Inc.
Assembly Biosciences reported positive clinical data across four antiviral programs in 2025: helicase-primase inhibitors 5366 and 1179 for recurrent genital herpes, hepatitis delta virus entry inhibitor 6250, and hepatitis B capsid assembly modulator 4334, none of which have received FDA approval. In December 2025, Gilead Sciences exercised its option to exclusively license the 5366/1179 herpes program, while Assembly retains 6250, 4334, and an early-stage NNPI program, 7272, for transplant-associated herpesviruses.
Assembly generates no product revenue; its near-term economics center on its Gilead collaboration, under which Gilead's December 2025 option exercise on the herpes program triggers a decision, expected by mid-2026, on whether Assembly opts into a Profit-Share arrangement rather than simply receiving milestone and royalty payments. For its wholly owned programs, 6250 targets the NTCP receptor shared by hepatitis B and D viruses to block viral entry, with Phase 2 initiation targeted for the fourth quarter of 2026, while 4334 is a next-generation capsid assembly modulator designed to block both ongoing HBV replication and the formation of new cccDNA, a viral reservoir no approved oral therapy directly targets; Assembly has initiated a structured process to find a partner for 4334 rather than advancing it alone. The company relies on contract research organizations and third-party manufacturers, including vendors located outside the United States and in China, for both clinical study conduct and product-candidate formulation and manufacturing.
Show full overview
Assembly's most advanced value driver, the genital herpes franchise, now sits entirely inside Gilead's control: the 10-K states the Gilead collaboration is expected to be a critical part of developing, manufacturing, and commercializing Assembly's product candidates, and once the ongoing Phase 1a/b studies of 5366 and 1179 conclude, all further clinical and regulatory decisions shift to Gilead's sole discretion. Assembly's only remaining lever is whether to opt into a Profit-Share once Gilead delivers a development plan and budget, a decision due by mid-2026 that determines whether Assembly captures upside beyond milestones and royalties. That leaves Assembly's economics on its most de-risked asset dependent on a partner's prioritization decisions rather than its own execution.
See also: Healthcare · Biotechnology
From Assembly Biosciences, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMcounterpartyGilead10-K Item 1A: 'We expect our collaboration with Gilead to be a critical part of the development, manufacture and commercialization of our product candidates.'
Material Events(8-K, last 90d)
- 2026-06-05Item 5.02LOWStockholders approved Amendment No. 3 to the 2018 Stock Incentive Plan (raising reserved shares to 2,678,333) and Amendment No. 2 to the Employee Stock Purchase Plan (raising reserved shares to 515,000) at the June 4, 2026 annual meeting; routine equity plan amendments.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -12.8% YoY. Growth thesis broken unless recovery story develops.static
Unprofitable operations — net margin -9.0%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.89: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $26.87. Score 4.1/10, moderate confidence.
Take-profit target: $42.50 (+47.1% upside). Prior stop was $26.87. Stop-loss: $26.87.
Quality below floor (1.4 < 4.0).
Assembly Biosciences, Inc. trades at a P/E of 346.8 (forward -13.2). TrendMatrix value score: 7.4/10. Verdict: Sell.
10 analysts cover ASMB with a consensus score of 4.3/5. Average price target: $50.
What does Assembly Biosciences, Inc. do?Assembly Biosciences is a clinical-stage biotechnology company developing antiviral therapeutics, including two...
Assembly Biosciences is a clinical-stage biotechnology company developing antiviral therapeutics, including two long-acting helicase-primase inhibitors for recurrent genital herpes (5366 and 1179, licensed to Gilead Sciences in December 2025), an oral hepatitis delta virus entry inhibitor (6250), a next-generation hepatitis B capsid assembly modulator (4334), and an early-stage NNPI program for transplant-related herpesviruses. The company has no approved products and expects its Gilead collaboration to be a critical part of developing, manufacturing, and commercializing its product candidates